The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 5 briefings matching “lipid”

Reset all filters

Endocrinology

Endocrinology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

ENDOCRINOLOGY · CLINICAL PRACTICE

Beyond singular effectors: The futile creatine cycle from molecular mechanism to integrated adipocyte thermogenesis

The FCC thus offers a reference point for connecting the biochemical mechanisms of other thermogenic cycles to their physiological contributions. They establish physiological relevance beyond what maximal respiratory rates in reductionist systems alone can reveal.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readCell MetabolismNov 3, 2026

ENDOCRINOLOGY · CLINICAL PRACTICE

Lipid organization in health and disease

In this Voices piece, our authors explore these themes through specific examples. Lipids are spatially and dynamically organized-within organelles, across cell types and organs, and in response to microbial and dietary inputs.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readCell MetabolismNov 3, 2026

ENDOCRINOLOGY · PHASE III

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial

In Japanese adults with obesity disease, once-daily orforglipron resulted in statistically superior reductions in bodyweight versus placebo (inactive comparison treatment), with a safety profile consistent with that of other GLP-1 receptor agonists. Orforglipron, a small-molecule, non-peptide, oral GLP-1 receptor agonist, has shown bodyweight reduction and cardiometabolic benefits in adults with obesity across Phase 3 trials globally.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Diabetes & EndocrinologyOct 30, 2026

ENDOCRINOLOGY · RANDOMIZED CLINICAL TRIAL

Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women

Interpretation is limited by the observational design, absence of a comparator group, self-pay population and 6-month follow-up. These findings support the feasibility of delivering structured, digitally enabled obesity pharmacotherapy at scale and provide prospective real-world implementation evidence for this care model.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readNature MedicineOct 16, 2026

ENDOCRINOLOGY · PHASE III

UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial

UBT251 produced weight reduction with cardiometabolic improvements and an acceptable safety profile, supporting Phase 3 evaluation. UBT251 is a novel triple agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readCell MetabolismOct 8, 2026

Interactive Fact Check